SG11202106668WA - Activatable masked anti-ctla4 binding proteins - Google Patents
Activatable masked anti-ctla4 binding proteinsInfo
- Publication number
- SG11202106668WA SG11202106668WA SG11202106668WA SG11202106668WA SG11202106668WA SG 11202106668W A SG11202106668W A SG 11202106668WA SG 11202106668W A SG11202106668W A SG 11202106668WA SG 11202106668W A SG11202106668W A SG 11202106668WA SG 11202106668W A SG11202106668W A SG 11202106668WA
- Authority
- SG
- Singapore
- Prior art keywords
- binding proteins
- ctla4 binding
- masked anti
- activatable masked
- activatable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862785111P | 2018-12-26 | 2018-12-26 | |
PCT/US2019/068538 WO2020139920A2 (en) | 2018-12-26 | 2019-12-26 | Activatable masked anti-ctla4 binding proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202106668WA true SG11202106668WA (en) | 2021-07-29 |
Family
ID=69326740
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202106498XA SG11202106498XA (en) | 2018-12-26 | 2019-12-26 | Anti-ctla4 antibodies and methods of use thereof |
SG11202106668WA SG11202106668WA (en) | 2018-12-26 | 2019-12-26 | Activatable masked anti-ctla4 binding proteins |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202106498XA SG11202106498XA (en) | 2018-12-26 | 2019-12-26 | Anti-ctla4 antibodies and methods of use thereof |
Country Status (14)
Country | Link |
---|---|
US (2) | US20220073613A1 (en) |
EP (2) | EP3902832A2 (en) |
JP (2) | JP2022516503A (en) |
KR (2) | KR20210142594A (en) |
CN (2) | CN113490688A (en) |
AU (2) | AU2019416220A1 (en) |
BR (2) | BR112021012536A2 (en) |
CA (2) | CA3123050A1 (en) |
EA (2) | EA202191785A1 (en) |
IL (2) | IL284382A (en) |
MX (2) | MX2021007768A (en) |
PH (2) | PH12021551498A1 (en) |
SG (2) | SG11202106498XA (en) |
WO (2) | WO2020139926A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4082572A4 (en) * | 2019-12-25 | 2024-03-06 | Bio Thera Solutions Ltd | Anti-ctla-4 monoclonal antibody, preparation method therefor, and application thereof |
WO2022094147A1 (en) * | 2020-10-28 | 2022-05-05 | City Of Hope | Bispecific anti-cd38-cd3 binders |
CA3209364A1 (en) * | 2021-03-01 | 2022-09-09 | Jennifer O'neil | Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer |
US20220306743A1 (en) * | 2021-03-01 | 2022-09-29 | Xilio Development, Inc. | Combination of ctla4 and pd1/pdl1 antibodies for treating cancer |
EP4323001A1 (en) * | 2021-04-11 | 2024-02-21 | Adagene Inc. | Combination therapies for treating cancer |
WO2023161853A1 (en) | 2022-02-23 | 2023-08-31 | Bright Peak Therapeutics Ag | Activatable il-18 polypeptides |
CN115960234B (en) * | 2022-10-27 | 2023-12-29 | 合肥天港免疫药物有限公司 | anti-CD 16A antibodies and uses thereof |
Family Cites Families (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
JP3101690B2 (en) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | Modifications of or for denatured antibodies |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
AU632065B2 (en) | 1988-09-23 | 1992-12-17 | Novartis Vaccines And Diagnostics, Inc. | Cell culture medium for enhanced cell growth, culture longevity and product expression |
ATE102631T1 (en) | 1988-11-11 | 1994-03-15 | Medical Res Council | CLONING OF IMMUNOGLOBULIN SEQUENCES FROM THE VARIABLE DOMAINS. |
CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5891693A (en) | 1990-01-25 | 1999-04-06 | Alusuisse Holdings A.G. | Recombinant DNA methods vectors and host cells |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
US5264365A (en) | 1990-11-09 | 1993-11-23 | Board Of Regents, The University Of Texas System | Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides |
US5508192A (en) | 1990-11-09 | 1996-04-16 | Board Of Regents, The University Of Texas System | Bacterial host strains for producing proteolytically sensitive polypeptides |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
EP0861893A3 (en) | 1991-09-19 | 1999-11-10 | Genentech, Inc. | High level expression of immunoglobulin polypeptides |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
WO1993016185A2 (en) | 1992-02-06 | 1993-08-19 | Creative Biomolecules, Inc. | Biosynthetic binding protein for cancer marker |
WO1993022332A2 (en) | 1992-04-24 | 1993-11-11 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
ATE196606T1 (en) | 1992-11-13 | 2000-10-15 | Idec Pharma Corp | THERAPEUTIC USE OF CHIMERIC AND LABELED ANTIBODIES DIRECTED AGAINST A DIFFERENTIATION ANTIGEN WHICH EXPRESSION IS RESTRICTED TO HUMAN B LYMPHOCYTES, FOR THE TREATMENT OF B-CELL LYMPHOMA |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
US5639635A (en) | 1994-11-03 | 1997-06-17 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
US6027888A (en) | 1996-04-05 | 2000-02-22 | Board Of Regents, The University Of Texas System | Methods for producing soluble, biologically-active disulfide-bond containing eukaryotic proteins in bacterial cells |
US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US6083715A (en) | 1997-06-09 | 2000-07-04 | Board Of Regents, The University Of Texas System | Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells |
ES2244066T3 (en) | 1997-06-24 | 2005-12-01 | Genentech, Inc. | PROCEDURE AND COMPOSITIONS OF GALACTOSILATED GLICOPROTEINS. |
DE69840412D1 (en) | 1997-10-31 | 2009-02-12 | Genentech Inc | METHODS AND COMPOSITIONS CONTAINING GLYCOPROTEIN GLYCOR FORMS |
EP1034298B1 (en) | 1997-12-05 | 2011-11-02 | The Scripps Research Institute | Humanization of murine antibody |
ATE375365T1 (en) | 1998-04-02 | 2007-10-15 | Genentech Inc | ANTIBODIES VARIANTS AND FRAGMENTS THEREOF |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US20030175884A1 (en) | 2001-08-03 | 2003-09-18 | Pablo Umana | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
ES2434961T5 (en) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Antibody glycosylation engineering to improve antibody-dependent cell cytotoxicity |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
BR0008758A (en) | 1999-01-15 | 2001-12-04 | Genentech Inc | Variants of parental polypeptides with altered effector function, polypeptides, isolated nucleic acid composition, vector, host cell, method for producing a polypeptide variant, method for treating a disorder in mammals and method for producing a variant fc region |
ES2571230T3 (en) | 1999-04-09 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedure to control the activity of an immunofunctional molecule |
CA2388245C (en) | 1999-10-19 | 2012-01-10 | Tatsuya Ogawa | The use of serum-free adapted rat cells for producing heterologous polypeptides |
NZ518764A (en) | 1999-12-29 | 2004-02-27 | Immunogen Inc | Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
PT1355919E (en) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Molecules with extended half-lives, compositions and uses thereof |
KR100988949B1 (en) | 2001-10-25 | 2010-10-20 | 제넨테크, 인크. | Glycoprotein compositions |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
CN1930288B (en) | 2002-04-09 | 2012-08-08 | 协和发酵麒麟株式会社 | Cells of which genome is modified |
JP4832719B2 (en) | 2002-04-09 | 2011-12-07 | 協和発酵キリン株式会社 | Medicine containing antibody composition for FcγRIIIa polymorphism patients |
JPWO2003085118A1 (en) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | Method for producing antibody composition |
AU2003236018A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa |
WO2003085102A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cell with depression or deletion of the activity of protein participating in gdp-fucose transport |
CA2481920A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition-containing medicament |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
EP3263596A1 (en) | 2002-12-16 | 2018-01-03 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
US20090010920A1 (en) * | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
WO2005035586A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Fused protein composition |
CA2542125A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase |
EA025962B1 (en) | 2003-11-05 | 2017-02-28 | Роше Гликарт Аг | ANTIBODIES HAVING INCREASED Fc RECEPTOR BINDING AFFINITY AND EFFECTOR FUNCTION |
EP1725249B1 (en) | 2003-11-06 | 2014-01-08 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
WO2005053742A1 (en) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | Medicine containing antibody composition |
US7981843B2 (en) | 2004-01-20 | 2011-07-19 | Kalobios Pharmaceuticals, Inc. | Antibody specificity transfer using minimal essential binding determinants |
PT2343380T (en) | 2004-11-16 | 2019-09-18 | Humanigen Inc | Immunoglobulin variable region cassette exchange |
US20070087005A1 (en) * | 2005-10-14 | 2007-04-19 | Lazar Gregory A | Anti-glypican-3 antibody |
CN106995495A (en) * | 2009-01-12 | 2017-08-01 | 希托马克斯医疗有限责任公司 | Modified antibodies composition and its preparation and application |
KR102492532B1 (en) * | 2015-05-29 | 2023-01-30 | 아게누스 인코포레이티드 | Anti-CTLA-4 Antibodies and Methods of Using The Same |
ES2963226T3 (en) * | 2016-12-07 | 2024-03-26 | Agenus Inc | ANTI-CTLA-4 antibodies and methods of their use |
WO2018207701A1 (en) | 2017-05-09 | 2018-11-15 | 日東電工株式会社 | Composition for optical members, optical member and image display device |
CN116478289A (en) * | 2017-05-19 | 2023-07-25 | 上海药明生物技术有限公司 | Novel CTLA-4 monoclonal antibody |
WO2018209701A1 (en) * | 2017-05-19 | 2018-11-22 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4) |
US20180339043A1 (en) * | 2017-05-26 | 2018-11-29 | Janux Therapeutics, Inc. | Modified antibodies |
-
2019
- 2019-12-26 JP JP2021538112A patent/JP2022516503A/en active Pending
- 2019-12-26 SG SG11202106498XA patent/SG11202106498XA/en unknown
- 2019-12-26 EA EA202191785A patent/EA202191785A1/en unknown
- 2019-12-26 CA CA3123050A patent/CA3123050A1/en active Pending
- 2019-12-26 SG SG11202106668WA patent/SG11202106668WA/en unknown
- 2019-12-26 CN CN201980093081.5A patent/CN113490688A/en active Pending
- 2019-12-26 AU AU2019416220A patent/AU2019416220A1/en active Pending
- 2019-12-26 EP EP19843033.2A patent/EP3902832A2/en active Pending
- 2019-12-26 WO PCT/US2019/068548 patent/WO2020139926A2/en unknown
- 2019-12-26 CA CA3122773A patent/CA3122773A1/en active Pending
- 2019-12-26 AU AU2019416216A patent/AU2019416216A1/en active Pending
- 2019-12-26 US US17/417,239 patent/US20220073613A1/en active Pending
- 2019-12-26 EP EP19845664.2A patent/EP3902833A2/en active Pending
- 2019-12-26 US US17/417,244 patent/US20220064301A1/en active Pending
- 2019-12-26 WO PCT/US2019/068538 patent/WO2020139920A2/en active Application Filing
- 2019-12-26 BR BR112021012536-1A patent/BR112021012536A2/en unknown
- 2019-12-26 BR BR112021012631A patent/BR112021012631A2/en unknown
- 2019-12-26 KR KR1020217023750A patent/KR20210142594A/en unknown
- 2019-12-26 MX MX2021007768A patent/MX2021007768A/en unknown
- 2019-12-26 CN CN201980091038.5A patent/CN113490687A/en active Pending
- 2019-12-26 EA EA202191784A patent/EA202191784A1/en unknown
- 2019-12-26 MX MX2021007769A patent/MX2021007769A/en unknown
- 2019-12-26 KR KR1020217023751A patent/KR20210141447A/en unknown
- 2019-12-26 JP JP2021538124A patent/JP2022516881A/en active Pending
-
2021
- 2021-06-23 PH PH12021551498A patent/PH12021551498A1/en unknown
- 2021-06-23 PH PH12021551500A patent/PH12021551500A1/en unknown
- 2021-06-24 IL IL284382A patent/IL284382A/en unknown
- 2021-06-24 IL IL284381A patent/IL284381A/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL284382A (en) | 2021-08-31 |
WO2020139920A2 (en) | 2020-07-02 |
US20220064301A1 (en) | 2022-03-03 |
EP3902832A2 (en) | 2021-11-03 |
CN113490687A (en) | 2021-10-08 |
AU2019416216A1 (en) | 2021-07-08 |
BR112021012631A2 (en) | 2021-12-14 |
CA3123050A1 (en) | 2020-07-02 |
KR20210141447A (en) | 2021-11-23 |
PH12021551500A1 (en) | 2022-02-28 |
WO2020139920A3 (en) | 2020-08-06 |
WO2020139926A2 (en) | 2020-07-02 |
WO2020139926A3 (en) | 2020-08-06 |
KR20210142594A (en) | 2021-11-25 |
EA202191785A1 (en) | 2021-11-29 |
MX2021007768A (en) | 2021-08-24 |
SG11202106498XA (en) | 2021-07-29 |
PH12021551498A1 (en) | 2022-02-28 |
US20220073613A1 (en) | 2022-03-10 |
EA202191784A1 (en) | 2021-10-20 |
AU2019416220A1 (en) | 2021-07-22 |
CN113490688A (en) | 2021-10-08 |
CA3122773A1 (en) | 2020-07-02 |
BR112021012536A2 (en) | 2021-09-14 |
IL284381A (en) | 2021-08-31 |
EP3902833A2 (en) | 2021-11-03 |
MX2021007769A (en) | 2021-09-23 |
JP2022516503A (en) | 2022-02-28 |
JP2022516881A (en) | 2022-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11202106668WA (en) | Activatable masked anti-ctla4 binding proteins | |
ZA201808160B (en) | Bispecific binding proteins and uses thereof | |
IL304144A (en) | Anti-ctla4 antibodies and uses thereof | |
EP3621994A4 (en) | Mesothelin binding proteins | |
IL281954A (en) | Heterodimeric fc-fused proteins | |
IL272064A (en) | Binding proteins 1 | |
EP3652212A4 (en) | Antibodies binding lag-3 and uses thereof | |
EP3503920A4 (en) | Anti-ctla4 antibodies | |
IL278943A (en) | Multi-specific binding proteins and improvements thereon | |
ZA202003641B (en) | Antibodies binding ctla-4 and uses thereof | |
EP3352760A4 (en) | Cd3 binding polypeptides | |
EP3544628A4 (en) | 4-1bb binding proteins and uses thereof | |
EP3380514A4 (en) | Cd131 binding proteins and uses thereof | |
GB201802338D0 (en) | Antigen binding proteins | |
DK3737402T3 (en) | Modificeret protein | |
SG11202001420VA (en) | Modular binding proteins | |
EP3445394A4 (en) | Alk7 binding proteins and uses thereof | |
ZA201906821B (en) | Anti-jagged1 antigen binding proteins | |
EP3439692A4 (en) | Plectin-1 binding antibodies and uses thereof | |
EP3700571A4 (en) | Alk7 binding proteins and uses thereof | |
IL284317A (en) | Pseudofab-based multispecific binding proteins | |
IL304317A (en) | Tgf-beta-rii binding proteins | |
ZA202003722B (en) | Modified globin proteins | |
GB201704006D0 (en) | Modified globin proteins | |
GB201703049D0 (en) | Single-strand binding protein |